Welcome to Cabometyx.se website. This website is intended for Sweden Healthcare professionals only.
Please confirm below that you are a registered healthcare professional.
I AM A SWEDEN HEALTHCARE PROFESSIONAL
Current clinical practice guidelines for the management of hepatocellular carcinoma (HCC) include those produced by the European Society for Medical Oncology (ESMO),11 updated in 201912, the European Association for the Study of the Liver (EASL), updated in 201813 and the National Comprehensive Cancer Network (NCCN), updated in 2019.14
Cabozantinib and the ESMO HCC guidelines
Strongly recommended (Grade I, A) as a second-line treatment for advanced HCC.11
For more info about the latest ESMO clinical practice guidelines on the diagnosis, treatment and follow-up of hepatocellular carcinoma:
Cabozantinib and the EASL HCC guidelines
Strong recommendation with a high level of evidence as a second-line treatment for advanced HCC.13
For more info about the EASL guidelines on the management of hepatocellular carcinoma:
Cabozantinib and the NCCN HCC guidelines
Recommended as a Category 1 (high level of evidence) second-line treatment for HCC.14
For more info about the NCCN guidelines on hepatobiliary cancers: